Form 8-K Aimmune Therapeutics, For: Mar 25
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- SpaceX shares fall as second lockup period ends
- Supermicro probe finds no senior management link to export violations
- Werewolf Therapeutics sells platform assets to EMD Serono for $33M
Aimmune Therapeutics (AIMT) PT Raised to $58 at RBC Capital
March 26, 2019 6:27 AM EDTRBC Capital analyst Kennen MacKay raised the price target on Aimmune Therapeutics (NASDAQ: AIMT) to $58.00 (from $55.00) while maintaining a Outperform rating.
ARTEMIS reads out positively in Europesetting the stage for a mid-19 MAA filing... More